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ABSTRACT 
 
Background: Oral cancer is a fatal disease with a bad prognosis. It is often preceded 
by oral potentially malignant disorders (OPMD). Cytokines Interleukin-8 (IL8) and 
Interleukin-1Beta (IL1B) are produced in a dysregulated fashion in oral cancer. 
Salivary levels of these cytokines may be early markers of malignant transformation of 
OPMD.  
Aim and Objective: To study the levels of Interleukin-8 and Interleukin1B in saliva 
of patients with oral squamous cell carcinoma (OSCC), oral potentially malignant 
disorders and normal controls. 
Materials and methods: Saliva from 18 subjects with OSCC, 16 subjects with Oral 
submucous fibrosis (OSF), 14 subjects with Leukoplakia (Dysplasia) and 24 normal 
patients constituted the study group. Salivary IL 8 and IL1B were analysed using solid 
phase sandwich Enzyme Linked Immunosorbant Assay (ELISA) technique. 
Results: Levels of salivary IL 8 and IL1B were significantly elevated in OSCC when 
compared to controls. OPMD showed no significant difference when compared to 
controls. 
Conclusion: Salivary levels of IL 8 and IL 1B are higher in OSCC than in OPMD and 
normal. The levels in OPMD and normal were similar. Based on our results, in a 
limited sample, the cytokine IL 8 is useful in identifying transformation of OPMD. IL 
1B shows potential in leukoplakia. 
Keywords: Saliva, Biomarker, Cytokines, Interleukin 8, Interleukin IB, Oral 
squamous cell carcinoma. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 Cancer is the leading cause of death in both economically developed countries 
and developing countries.
1
 Globally 12.7 million cancer cases and 7.6 million cancer 
deaths occurred in 2008.
2 
Of this oral cavity cancer (including lip cancer) accounted 
for 263,900 new cases and 128,000 deaths. In India out of 5,56,400 cancer deaths in 
2010, 45000 cases were due to oral cancer which makes it one of the most fatal disease 
in the country. Among 84000 tobacco related cancers there were twice as many deaths 
from oral cancers than lung cancers.
3, 4   
   
More than 95% of the carcinomas of the oral cavity are squamous cell 
carcinomas. Carcinoma of oral cavity in males, in developing countries, is the sixth 
commonest cancer after lung, prostrate, colorectal, stomach and bladder cancer, while 
in females; it is the tenth most common site of cancer after breast, colorectal, lung, 
stomach, uterus, cervix, ovary, bladder and liver.
5
  
Studies including a recent study in 2012 reaffirmed that oral cancer forms a 
major part of the cancer load in parts of India.
3,6 
Tobacco and arecanut are the two 
most important known risk factors for the development of oral cancer.
7,8 
Cofactors in 
development of Oral Squamous Cell Carcinoma (OSCC) include dietary factors, 
immunodeficiency and viral infections like HPV 16/18
6
. 
Though the oral cavity is very accessible to routine examination oral cancer has 
bad prognosis because it is usually diagnosed in late stages. OSCC is often preceded 
by Oral Potentially Malignant Disorders (OPMD) such as leukoplakia, erythroplakia, 
erosive lichen planus and Oral Submucous Fibrosis (OSF). The malignant conversion 
of OPMD can to some extent be predicted by histopatholgical findings. Moderate 
dysplasia has 4-11% chances of malignant transformation
 .
and severe dysplasia has 20-
35% chances of malignant transformation.
9
  Surrogate biomarkers help in identifying 
 the lesions that carry a higher risk of malignant transformation. Salivary biomarkers 
are gaining importance because of their ease of accessibility, patient compliance and 
advances in technique that enable identification of specific markers.
9,10, 11, 12 
Salivary levels of Interleukin 8 (IL8) and Interleukin I Beta (IL1B) are known 
to be elevated in oral cancer.
10, 11 
 They are chemokines that are deregulated in oral 
squamous cell carcinoma. Chemokines regulate growth, trafficking, signalling, 
differentiation of stromal and tumor cells, affect the tumor microenvironment and 
influence the behaviour of malignant cells
12 
Elevated IL-1B concentrations have been identified in tumors of breast, colon, 
lung, head and neck cancers, and melanomas with poor prognoses.
13.14.15,16,17
 IL1B 
promotes tumor proliferation, angiogenesis, and metastases through autocrine and 
paracrine effects within the tumor and in the microenvironment.
18
 While the exact 
mechanisms by which IL-1B promotes tumor growth remain unclear the protein is 
believed to act by induction of pro-metastatic genes such as matrix metalloproteinases 
and through paracrine stimulation angiogenic proteins and growth factors such as 
VEGF, IL-8, IL-6, TNFalpha, and TGF. 
19
                                                 
IL 8 is a pro-inflammatory chemokine which exerts multiple effects on 
different cell types present in the tumor and its microenvironment. Tumor derived IL 8 
can increase the proliferative activity of tumor cells, enhance the survival and promote 
angiogenesis by inducing the endothelial cells. Moreover, it can also activate the 
tumor-associated macrophages which lead to the secretion of additional growth 
factors. These growth factors further increase the rate of cell proliferation and 
invasion.
20
     
 
 Saliva as a diagnostic tool has the potential to identify altered levels of 
cytokines in oral malignant and potentially malignant disorders.
9,10.46
 The purpose of 
this study was to study the levels of IL8 and IL1B in saliva in patients with oral 
malignant and potentially malignant disorders and ascertain their relevance in OSCC 
and OPMD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and Objectives 
 
 AIM:  
To detect the levels of IL8 and IL1B in saliva of patients with OSCC, OPMD 
and control group (Normal). 
 
OBJECTIVES: 
1. To study the levels of IL8 and IL1B in saliva of patients with OSCC by using 
solid phase sandwich ELISA with biotinylated  IL8 and IL1B antibodies 
(Diaclone
TM
France)(Annexure I and II). 
2. To study the levels of IL8 and IL1B in saliva of patients with OPMD (oral 
submucous  fibrosis and leukoplakia) by using solid phase sandwich ELISA 
with biotinylated  IL8 and IL1B antibodies (Diaclone
TM
France). 
3. To study the levels of IL8 and IL1B in saliva of normal controls including 
patients with periodontitis and patients without periodontitis by using solid 
phase sandwich ELISA with biotinylated  IL8 and IL1B antibodies 
(Diaclone
TM
France). 
 
NULL HYPOTHESIS: 
 IL8 and IL1B levels are similar in saliva of patients with OSCC, OPMD (Oral 
submucous fibrosis and Leukoplakia) and controls (Normal). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods
 
 
 METHODOLOGY 
Institutional Review Board (IRB) approval was obtained(Annexure III) for the 
given project. All samples were collected after obtaining consent from the subjects. 
(Annexure IV). 
 
Groups: 
Group I   - Oral squamous cell carcinoma patients, n=18 
Group II  - Oral potentially malignant disorders, n=30  
 Group IIA - Oral submucous fibrosis, n=16  
 Group IIB - Leukoplakia, n=14 
Group III - Normal controls, n=24  
 Group IIIA - With periodontitis, n=12  
 Group IIIB - Without periodontitis, n=12    
 
DIAGNOSTIC CRTERIA    
OSCC - Histologically diagnosed Squamous cell carcinoma of oral cavity 
(excluding lip). 
OSF - Oral submucous fibrosis which is an insidious, chronic disease affecting 
any part of the oral cavity and sometimes the pharynx. Occasionally it is preceded by 
and/or associated with vesicle formation and is always associated with a juxtaepithelial 
inflammatory reaction followed by progressive hyalinization of the lamina propria.  
Leukoplakia - Those with Epithelial dysplasia in clinically diagnosed 
Leukoplakia should be used to recognize white plaques of questionable risk having 
excluded (other) known diseases or disorders that carry no increased risk for cancer.  
 Inclusion criteria for group I subjects: 
 Patients with Squamous cell carcinoma of oral cavity in the following sites : 
Buccal  mucosa, tongue, gingiva, alveolus, hard and soft palate. 
 Patients should not have undergone any treatments (chemotherapy, radiotherapy, 
surgery or any alternative remedies) 
 
Inclusion criteria for group II subjects: 
 Patients with Oral potentially malignant disorders (Oral submucous fibrosis and 
Leukoplakia with histologically diagnosed epithelial dysplasia) 
 
Exclusion criteria for group I and II subjects: 
 Any prior malignancy 
 Fever at present or for the past one month 
 Immunodeficiency – immune-suppression in transplant patients, HIV infection 
 Autoimmune disorders(arthritis, psoriasis, inflammatory bowel disease, 
Sjogren’s syndrome) 
 Hepatitis virus infection 
 
Inclusion criteria for group III subjects: 
Subjects without periodontitis 
 Healthy, age and gender matched subjects. 
 Subjects without periodontitis and other metabolic and systemic diseases. 
Exclusion criteria for group III subjects 
 Subjects with any pathology of oral mucosa. 
 Criteria used for assessing Periodontitis
21
            
1. Plaque scores                    more than 30% of sites 
2. Bleeding scores                more than 30% of sites 
3. Pocket depth                   greater than or equal to 3mm 
4. Clinical attachment loss (CAL)   greater than or equal to 2mm 
Pocket depth is measured from the gingival margin to the base of the sulccus 
and clinical attachment loss is measured from the cement-enamel junction to the base 
of the pocket. All the parameters are measured fron six sites per tooth – mesio-buccal, 
mid-buccal, distobuccal, mesio-lingual, mid-lingual and disto-lingual. 
 
METHOD OF COLLECTING SALIVA: 
22 
Unstimulated whole saliva was collected at a specific time interval, between 9 
to 12 am either before breakfast or one hour after having breakfast. Subject is seated in 
a semi reclined comfortable position. 
 The subjects were asked to avoid brushing teeth within 1 hour prior to collection, 
using salivary stimulants: chewing gum, lemon drops, granulated sugar, 
consuming a major meal within 1 hour prior to collection and consuming acidic 
or high sugar foods within 20 minutes prior to collection. 
 The subjects were given drinking water (bottled) and asked to rinse their mouth 
out well (without drinking the water).  
 Five minutes after this oral rinse, the subjects were asked to spit whole saliva 
(WS) every minute for 5 to10 minutes without swallowing to the sterile 
container. 
  Subjects were advised to refrain from talking, drop down the head and let the 
saliva run naturally to the front of the mouth, hold for a while and spit into the 
sterile container provided about once a minute for up to 10 minutes.  
 Subjects were advised not to cough up mucus or vomit. (Samples diluted with 
mucus or vomits were discarded).   
 Collected samples were labelled with a sample identification number and placed 
on ice for transport.  
 The case history and all medications taken and prescribed were recorded with 
time & date of sample collection. 
Storage of the samples: 
1. Collected samples are centrifuged at -10 to -20 degree centigrade at 3500rpm for 
15- 20mts. 
2. The supernatant and the sediment is stored separately, the sediment (pellet) is 
kept in the centrifuged tube and marked. 
3. The supernatant is aliquoted into separate micro centrifuge tubes (eppendorf) by 
pippeting approximately 1.5ml into each tube. 
4. The supernatant and pellet are stored at -70 degree Celsius till processing. 
 
  
 EQUIPMENTS AND CHEMICAL REAGENTS NEEDED: 
1. Oral examination devices 
Mouth mirror, Williams probe, disposable gloves and mask 
2. Elisa kit for IL8 and IL1B 
3. Elisa reader 
4. Incubator 
5. Autoclave 
6. 10, 50, 100, and 200 µl micropipettes and disposable pipette tips 
7. Timer 
8. Disposable vials and troughs 
9. Deionized water 
10. Absorbent tissue 
11. Negative 70 degree centigrade ultra low temperature storage cabinet 
12. Labels 
13. PBS  
14. Polypropylene conical tube 
15. Centrifuge Tubes 
16.  Laboratory Centrifuge 
17.  Sterilized containers for saliva collection 
18.  Ice pack ( for transfer )                                    
 
 
 
 
 PROCEDURE:   
Enzyme linked Immunosorbant Assay (ELISA) 
 Solid phase sandwich ELISA for IL8 and IL1B was used for quantitative 
determination of salivary IL8 and IL1B levels respectively. (Manufacturer – 
Diaclone
TM
) 
 
PRINCIPLE OF THE ASSAY 
 The wells of the microtitre strip plate have been coated with a capture antibody 
highly specific for IL8 and IL-1B provided during manufacture.  
 Binding of IL8 and IL1B in samples and known standards to the capture 
antibodies and subsequent binding of the biotinylated anti-IL8 and IL-1B 
secondary antibody to the analyte is completed during the same incubation 
period. Any excess unbound analyte and secondary antibody was removed. 
 The HRP conjugate solution is then added to every well including the zero wells, 
following incubation excess conjugate is removed by careful washing.  
 A chromogen substrate is added to the wells resulting in the progressive 
development of a blue coloured complex with the conjugate.  
 The colour development is then stopped by the addition of acid turning the 
resultant final product yellow.  
 The intensity of the produced coloured complex is directly proportional to the 
concentration of IL8 and IL-1B present in the samples and standards.  
 The absorbance of the colour complex is then measured and the generated values 
for each standard are plotted against expected concentration forming a standard 
curve.(Annexure V)  
  The absorbance value is measured on a spectrophotometer using a wavelength of 
450 nm.  
 The standard curve was then used to determine the concentration of IL 8 and IL-
1B in the samples tested. 
 
PREPARATION OF REAGENTS  
 The kit was stored at 2-80C after procurement and all the reagents were brought 
to room temperature before used. 
 Preparation of Wash Buffer was done by diluting the wash buffer concentrate 
200 fold with distilled water to give a 1x working solution. Entire contents (10 
ml) of the Washing Buffer Concentrate was poured into into a clean 2,000 ml 
graduated cylinder and final volume was made to 2,000 ml with glass-distilled or 
deionized water.    
 Preparation of Standard Diluent Buffer was done by adding the contents of the 
vial (10x concentrate) to 225ml of distilled water before use. 
 Standard was prepared by reconstituting the standard vials using standard 
diluents for serum and plasma 
 This reconstitution gives a stock solution of 2000pg/ml of IL-8 and 500pg/ml of 
IL 1B.  
 Control was prepared by reconstituting freeze-dried control vials with the 
Standard Diluent  for serum and plasma. 
 Preparation of Biotinylated anti-IL-8 was done immediately before use by 
diluting the biotinylated anti-IL-8 with the biotinylated antibody diluent in a 
clean glass vial using volumes appropriate to the number of required wells. 
  Streptavidin-HRP was prepared by diluting the 5µl vial with 0.5ml of HRP 
diluent immediately before use. 
 
SERIAL DILUTION OF STANDARD 
 Reconstituted standard was mixed gently by repeated aspirations/ejections. 
 Serial dilutions of the standard are made directly in the assay plate to provide the 
concentration range from 2000 to 62.5pg/ml.  
 Immediately after reconstitution  200µl of the reconstituted standard  was added 
to wells A1 and A2, which provides the highest concentration standard at 
2000pg/ml 
 100µl of appropriate standard diluent was added to the remaining standard wells 
B1 and B2 to F1 and F2 
 100µl from wells A1 and A2 was aspirated, added  to B1 and B2 and mixed by 
repeated aspirations and ejections taking care not to scratch the inner surface of 
the wells 
 This 1:1 dilution was continued by using 100µl from wells B1 and B2 through to 
wells F1 and F2 providing a serial diluted standard curve ranging from 
2000pg/ml to 62.5pg/ml for IL 8 and from 500pg/ml to15.6pg/ml of IL 1B. 
 
 
 
 
 
 
 FLOWCHART OF EXPERIMENT 
 
Add 100 µl of sample and diluted standard/controls and 50µl Biotinylated anti-IL-8 
 
Incubate 1 hours at room temperature for IL 8 and 3 hours for IL 1B 
 
Wash three times 
 
Add 100μl of Streptavidin-HRP 
 
Incubate 30min at room temperature 
 
Wash three times 
 
Add 100μl of ready-to-use TMB. Let the color develop for 12-15 mn. 
 
Add 100μl H2SO4 
 
Read Absorbance at 450 nm 
 
 
 
 
 
 STATISTICS  
Sample Size 
            The sample size of 30 in each group has been determined from the Standard 
Statistical Table (Expecting a large effect size of 0.4 to detect the minimum difference 
between control and study groups under an approximate power of 0.9 with the level of 
significance of 0.05). 
           
The allotted study period was 10 months. Only 72 cases satisfying the criteria 
was obtained in the time period of the study and hence the sample size was reduced as 
shown below. 
TYPE OF SAMPLE SAMPLE SIZE 
Oral squamous cell carcinoma 18 
Oral submucous fibrosis 16 
Leukoplakia 14 
Controls with periodontitis 12 
Controls without periodontitis 12 
 
Statistical Analysis 
Data entry and analysis was done using SPSS (Statistical Package of Social 
Science
TM
) version 17. The differences in means between more than one group were 
assessed using Analysis Of Variance (ANOVA)test and multiple comparisons were 
done using Tukey HSD test. P value of < 0.05 was considered to be statistically 
significant.      
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
 Cancer is a potentially fatal disease affecting a significant part of the 
population and one of the leading causes of death worldwide. In India, the 
International Agency for Research on Cancer estimated indirectly that about 635000 
people died from cancer in 2008, representing about 8% of all estimated global cancer 
deaths and about 6% of all deaths in India.
3
  
Oral cancer is a serious debilitating disease and a growing problem in India as 
well as in many parts of the world. Oral and pharyngeal cancer, grouped together, is 
the sixth most common cancer in the world. 
23       
      
 
ORAL SQUAMOUS CELL CARCINOMA 
 Oral cancer remains a lethal disease for over 50% of cases diagnosed 
annually
24
. Smoking, smokeless tobacco products, alcohol use, arecanut and HPV 
infections are the major risk factors for oral cavity cancer, with smoking and alcohol 
having synergistic effects. The contribution of each of these risk factors to the burden 
varies across regions.  Accordingly there is a significant difference in the incidence of 
oral cancer in different regions of the world. The age-adjusted rates of oral cancer vary 
from over 20 per 100,000 populations in India, to 10 per 100,000 in the U.S., and less 
than 2 per 100,000 in the Middle East.
17
 Smoking accounts for 42% of deaths from 
cancers of the oral cavity (including the pharynx) and heavy alcohol consumption for 
16% of the deaths worldwide. In high-income countries, smoking and alcohol 
consumption accounts for 70% and 30% of cancer deaths, respectively. At the same 
time in India, Taiwan, and other neighbouring countries smokeless tobacco products, 
arecanut and betel quid with or without tobacco are the major risk factors for oral 
cavity cancer. 
7  
 The global burden of cancer continues to increase largely because of the aging 
and growth of the world population and an increasing adoption of cancer-causing 
behaviours, particularly smoking, within economically developing countries. More 
than 95% of the carcinomas of the oral cavity are of squamous cell type, in nature. 
They constitute a major health problem in developing countries, representing a leading 
cause of death. The survival index continues to be small (50%), as compared to the 
progress in diagnosis and treatment of other malignant tumors. In India, 60-80% of 
patients present with advanced disease as compared to 40% in developed countries. 
6
  
 This is reflected by the fact that despite easy accessibility of the oral cavity for 
regular examination most cases are in advanced stages at the time of detection and the 
survival rate for oral cancer has remained essentially unchanged over the past three 
decades. Detecting oral cancer in early stages, when these are amendable to single 
modality therapies, offers the best chance of long term survival.
25
  
 
ORAL SUBMUCOUS FIBROSIS 
Oral submucous fibrosis (OSF) is an insidious, chronic disease affecting any 
part of the oral cavity and sometimes the pharynx. Occasionally it is preceded by 
and/or associated with vesicle formation and is always associated with a juxtaepithelial 
inflammatory reaction followed by progressive hyalinization of the lamina propria. 
Different populations may show different sites of involvement within the mouth.
26
 The 
etiology of OSMF is mainly attribauted to the use of areca nut predominantly found in 
India. Other etiologic factors such as chillies, lime, tobacco, nutritional deficiencies 
such as iron and zinc, immunological disorders, and collagen disorders also have been 
suggested.
27 
 
 Commercially available products such as pan masala, betel quid, guthka and 
mawa have high concentrates of areca which interferes with the molecular processes of 
deposition and/or degradation of extracellular matrix molecules such as collagen. The 
habit of chewing pan masala has been found to be associated with OSMF more than 
betel quid chewing. Direct correlation was seen in occurrence of OSMF with 
frequency rather than duration of chewing.
28 
 
 
The early and late forms of presentation 
outlined in OSMF are well recognized as a potentially malignant disorder. 
29 
OSMF 
has a high rate of morbidity because it causes a progressive inability to open the 
mouth, resulting in difficulty in eating and consequent nutritional deficiencies. OSMF 
also has a significant mortality rate as it has potential to transform into oral cancer, 
particularly squamous cell carcinoma, at a rate of 7.6%.
29  
Early detection and 
management of OSMF can significantly reduce the mortality and morbidity associated 
with it.
30
  
DYSPLASIA 
Many oral cancers pass through a premalignant phase (dysplasia or carcinoma 
in situ), whereas others appear to arise de novo without clinical or microscopic 
evidence of a pre-existing lesion. This includes leukoplakia, erythroplakia, oral 
submucous fibrosis, actinic keratosis, erosive lichen planus etc.
31,32
 At present, biopsy 
is mandatory considering the malignant potential of these lesions. Histopathological 
examination of haematoxylin and eosin stained sections for the presence of epithelial 
dysplasia is currently the gold standard for assessment of potentially malignant 
disorders.  
  ‘The term leukoplakia should be used to recognize white plaques of 
questionable risk having excluded (other) known diseases or disorders that carry no 
increased risk for cancer’. 31  About 50% of biopsied leukoplakias show dysplasia and 
overall the rate of malignant transformation in leukoplakia is only about 0.1 - 2% per 
year. Higher rates of about 20% have been reported in non-homogeneous lesions 
which are more likely to show dysplasia on biopsy.
33 
The malignat conversion of 
precancerous lesions and conditions can to some extent predicted by histopatholgical 
findings: Moderate dysplasia has 4-11% chances of malignant transformation
 
and 
severe dyplasia has 20-35% chances of malignant transformation.
7  
 
 
BIOMARKERS 
Hulka and colleagues defined biomarker as “Cellular, biochemical or 
molecular alterations that are measurable in biological media such as human tissues, 
cells, or fluids.”34 These are biological characteristics that can be objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention. In practice, biomarkers 
include tools and technologies that can aid in understanding the prediction, cause, 
diagnosis, progression, regression, or outcome of treatment of disease.
35 
Many 
biomarkers has been studied and validated in serum and saliva for various oral and 
systemic diseases.    
 
SALIVA 
         Saliva is a clear, slightly acidic and complex biological fluid composed of 
secretions from major salivary glands: the parotid, submandibular, and sublingual 
 glands, as well as multitudes of minor glands including labial, buccal, lingual, and 
palatal tissues. In general, human salivary glands produce about 1–1.5 L of serous and 
mucinous saliva daily by combining water, salts, and an abundance of molecules from 
the blood with a cocktail of salivary proteins in the oral cavity to give rise to the multi-
constituent whole saliva. The pH of saliva ranges from 6.0–7.0.36  
 
CHEMICAL COMPOSITION AND FUNCTIONS OF SALIVA 
 Water is the major constituent of saliva (97%), besides water salivary fluid 
contains proteins, post-translationally modified proteins (e.g., glycoproteins, 
phosphoproteins), peptides, lipids, minerals, and other small compounds. Upon release 
of glandular secretions into the oral cavity, the fluid is mixed with a variety of 
exocrine, nonexocrine, cellular, and exogeneous components to ultimately form whole 
saliva (WS). Whole saliva is a complex fluid which consists of salivary secretions 
from different salivary glands, sloughed oral epithelial cells, nasopharyngeal 
discharge, food debris, gingival crevicular fluid, bacteria and their products.
37  
  
Saliva has several types of functions that are of profound importance for the 
oral health.
38   
It include digestion, antimicrobial activity, buffering capacity, 
lubrication cleansing action etc. All these function are carried out by the proteins, 
enzymes and other compounds present in saliva (Annexure VI).
 
 Saliva is a complex 
fluid containing a variety of enzymes, hormones, antibodies, inflammatory markers, 
antimicrobial constituents, and growth factors. Many of these enter saliva from the 
blood by passing through the spaces between cells by transcellular or paracellular 
routes. Therefore, most compounds found in blood are also present in saliva, thus 
 saliva is functionally equivalent to serum in reflecting the physiological and disease 
states of the body. 
 
SALIVA PHYSIOLOGY 
 Oral fluid is primarily composed of water (97%) electrolytes, immunoglobins, 
enzymes and proteins.
39   
The salivary glands are composed of specialized epithelial 
cells which are of two types:  the acinar and ductal cells. The fluid is generated and 
most of the protein synthesis and secretion takes place in the acinar region. Amino 
acids enter the acinar cells by means of active transport, and after intracellular protein 
synthesis, the majority of proteins are stored in storage granules that are released in 
response to secretory stimulation. The initial fluid is isotonic in nature and is derived 
from the local vasculature. While acinar cells are water-permeable, ductal cells are not. 
The ductal cells actively absorb most of the Na
+
 and Cl
-
 ions from the primary salivary 
secretion and secrete small amounts of K
+
 and HCO3 and some proteins. The primary 
salivary secretion is thus modified, and the final salivary secretion as it enters the oral 
cavity is hypotonic.
37  
  
Salivary secretions are classified as serous, mucous, or mixed. Serous 
secretions contain more water than mucous. Different salivary glands produce saliva 
with a characteristic protein composition. When salivary flow is unstimulated, such as 
in resting saliva; the submandibular contributes a major percentage to whole saliva 
volume followed by parotid, sublingual and minor salivary glands respectively 
(Annexure VI). Although the minor salivary glands are not major contributors to the 
whole-saliva volume, they play a significant role in the lubrication and protection of 
the oral mucosa because of their mucous secretions. Parotid gland secretion is purely 
 serous, and submandibular and sublingual gland secretions are mixed (mucous and 
serous).  
The primary saliva, formed by the acinar cells, has an ionic composition 
similar to that of plasma. It is modified by the ductal cells to a hypotonic solution by 
reabsorption of sodium and chloride without water.
37.
 The flow rate of resting saliva 
for all three glands is very low, approximately one-tenth of that during stimulated 
flow. The total amount of saliva secreted varies among individuals and environmental 
factors.
39  
 Stimulation affects the quantity of saliva, the concentrations of some 
constituents and the pH of the fluid
40
. 
Salivary flow rate, which can increase to 10 ml/min when stimulated, 
influences oral fluid pH. The bicarbonate content of oral fluid increases with 
stimulation. Circadian rhythms, physical activity and health status of the individual 
also influence physiology and flow rate of oral fluid.
41
 
 
SALIVA AS A DIAGNOSTIC FLUID 
Saliva is a clinically informative, biological fluid that is useful for novel 
approaches to prognosis, laboratory or clinical diagnosis, and monitoring and 
management of patients with both oral and systemic diseases. Saliva can reflect the 
physiologic state of the body, including emotional, endocrinal, nutritional and 
metabolic variations and acts as a source for the monitoring of oral as well as systemic 
health. The application of saliva has dramatically got expanded due to the 
technological advances for the past two decades. The achievements of high-throughput 
approaches afforded by biotechnology and nanotechnology allow for disease-specific 
salivary biomarker discovery and establishment of rapid, multiplex, and miniaturized 
 analytical assays. The avenue of saliva diagnostics incorporating transcriptomic, 
proteomic and metabolomic findings will enable the use of salivary biomarkers to 
diagnose a disease state and to monitor the progression remission and reoccurrence of 
diseases and therapeutic outcomes. 
42  
.Salivary diagnostics is an emerging field that 
has tremendous potential in clinical applications because its collection is non-invasive 
and it contains a wide spectrum of analytes which can serve as biomarkers for 
assessment of oral and systemic health. 
Saliva clearly meets the demands for an inexpensive, noninvasive, and easy-to-
use screening method. As a diagnostic specimen in the clinic, saliva has many 
advantages in terms of collection, storage, shipping, and voluminous sampling; all of 
these processes can be carried out very economically compared with serum or urine. 
Saliva is also easier to handle during diagnostic procedures than blood because it does 
not clot, thus reducing the number of manipulations required. Moreover, for healthcare 
professionals, a salivary test is safer than using serum, which is more likely to expose 
operators to blood-borne diseases. For the patients or examinees, the non-invasive 
collection approach could dramatically reduce anxiety and discomfort, and increase 
their willingness to undergo health inspections that will greatly increase the 
opportunity to monitor their general health over time and to diagnose morbidities in 
the early stage.
43,44,45,46
    Composition of saliva is influenced directly or indirectly by 
oral and systemic diseases. Early detection, diagnosis and assessment of prognosis of 
various diseases could be possible by monitoring the composition of saliva. Many 
studies have been done to identify potential biomarkers in saliva for oral as well as 
systemic diseases. 
 
 The significance of salivary biomarkers in many oral diseases has been 
evaluated including periodontitis, oral cancer
10,11,
  OPMD
46 
 and oral lichen planus.
47
   
None the less it has been also assessed in many systemic diseases like diabetes
48 
cardiac diseases,
49 
Sjogren syndrome
50,51
 and infectious diseases like HIV
42
and 
Helicobacter pylori
52
  infections. Moreover role of saliva in monitoring the levels of 
hormones and drugs have also been studied and evaluated. Point of care devices like 
Oral-AQ Oral Fluid Drugs of Abuse Rapid Test
®
 for drug abuse and OraQuick
® 
for 
HIV is commercially available. 
 
COLLECTION OF SALIVA SAMPLE 
The saliva sample can be collected in two ways: stimulated and unstimulated. 
Stimulated saliva can be collected after stimulation of salivary secretion using paraffin 
wax or citric acid. Unstimulated saliva is collected in the resting state. The 
submandibular glands are the major contributors to resting (unstimulated) saliva, and 
the parotid glands are the major contributors to stimulated saliva. The contribution of 
sublingual glands to unstimulated and stimulated whole saliva is low.  
 
METHODS OF COLLECTING SALIVA
53 
Several methods for collecting saliva have been reported and tested for validity 
and reproducibility. There are different methods for collection of whole saliva and 
gland specific saliva. Salivary constituents vary depending on the harvesting method 
and the degree of salivary flow. Irrespective of the method used, subjects should be 
instructed to clean the oral cavity before collection by rinsing the mouth thoroughly 
with water to avoid contaminants. 
  
STIMULATED SALIVA 
Stimulated saliva is usually collected by inducing masticatory action on 
paraffin wax or chewing gum (i.e. absorbent method) or gustatory stimulation by 
application of citric acid on the subject's tongue to increase the salivary flow rate. This 
method obviously affects the quantity and pH of the saliva, and is generally only used 
in patients who have difficulty in producing enough saliva
53
  
 
UNSTIMULATED SALIVA 
Unstimulated saliva is collected without exogenous facilitation, and its flow 
rate is mostly affected by the degree of hydration, olfactory stimulation, exposure to 
light, seasonal and diurnal factors. The three most common approaches for collection 
of unstimulated saliva are draining, spitting, and suction methods
43  
 
METHODS FOR COLLECTION OF WHOLE SALIVA 
PASSIVE DROOL 
A convenient method often used is the collection of whole saliva by passive 
drool into a small vial. Passive drool is highly recommended because it is approved for 
use with almost all analytes, unlike absorbent devices, which can sometimes cause 
interference in immunoassays. It is important to use high-quality polypropylene vials, 
since other vials can lead to problems with analyte retention or the introduction of 
contaminants that can interfere with the immunoassay. The vials use must also seal 
tightly and be able to withstand temperatures as low as -80ºC
37 
 
 ORAL SWAB 
Oral Swab is an excellent alternative to passive drool because of its ease of use. 
The oral swab is made of a non-toxic, inert polymer shaped into a 30 x 10 mm 
cylinder. It is not recommended for children under the age of six due to the possibility 
of a choking hazard
54 
 
COLLECTION OF GLAND SPECIFIC SALIVA 
Saliva from individual glands is not contaminated with food debris and 
microorganisms, so it is prudent to acquire saliva from individual major glands. The 
techniques are tedious and require custom-made collection devices. 
PAROTID GLAND: The parotid gland secretion is voided in the oral cavity via the 
Stensen duct at the vicinity of the parotid papilla opposite the maxillary second molar. 
A modified Lashley cup or Carlson-Crittenden collector often is used for collecting 
saliva from the parotid glands.
53 
SUBMANDIBULAR AND SUBLINGUAL GLANDS: The submandibular and 
sublingual gland secretions are voided in the oral cavity via the Wharton duct, which 
opens into the floor of the mouth. Many custom-made collectors such as the Wolff 
collector are used  
MINOR SALIVARY GLANDS: Minor salivary gland secretions do not have much 
clinical application, owing to the labor-intensive nature of collecting them. Specific 
methods like palatal acrylic devices are used to measure minor salivary gland 
secretions.
37 
 
 
 
 TECHNIQUES FOR ANALYSIS OF SALIVA 
Salivary diagnostics is a dynamic and emerging field in the diagnosis of oral 
and systemic diseases. Saliva is highly informative and has a potential for new 
approaches to prognosis, laboratory or clinical diagnosis, and monitoring and 
management of patients with both oral and systemic diseases. Many different 
techniques have been used for the past two decades for the analysis of saliva. Out of 
these techniques proteomics revealed disease specific biomarkers for various 
pathologic conditions. This would eventually lead to the invention and establishment . 
 
PROTEOMICS 
          ‘Proteomics is a multifaceted approach to study various aspects of protein 
expression, post-translational modification, interactions, organization and function at a 
global level
43 
. Saliva harbours a dynamic proteome with a wide range of proteins. The 
analysis of salivary proteome is indeed a challenging procedure as it contains a large 
number of proteins within an extremely wide concentration range. Different proteomic 
technologies have been used for detection and quantification of the salivary proteome. 
Based on advanced mass spectrometry different protein separation technologies have 
been used specifically or in combinations. The process of initial biomarker 
fractionation is required for mass spectrometry based proteomic techniques. Each 
fraction or spot of a protein is subjected to certain mass-spectrometric technology. The 
mass data obtained as a result is then used to search protein, geneomic expressed 
sequence tag (EST), and other species-specific databases to identify proteins present in 
each selected spot
55
. By comparing different samples, the changes in level of 
 expression of individual proteins can be identified and quantified. This permits the 
identification of biomarkers associated with specific pathologic or physiologic states.  
There are four different techniques used individually or in combination in 
biomarker screening and identification.  These include matrix-assisted laser desorption 
ionization – time of flight/mass spectrometry (MALDI-TOF/MS), 2DE, 2D-liquid 
chromatography /mass spectrometry (LC/MS), and surface enhanced laser desorption/ 
ionization time-of-flight mass spectrometry (SELDI-TOF/MS).
56
  
In a study Shotgun proteomics based on reversed phase liquid chromatography 
(LC) off-line prefractionation of intact proteins and subsequent LC-tandem mass 
spectrometry (LC-MS/MS) analysis of proteolyzed peptides was used for profiling of 
saliva proteins from OSCC or matched control subjects. Identification of the peptides 
and represented proteins was done by using the Mascot database search engine. 
52proteins were found to be present in OSCC but are absent in the healthy control 
subjects whereas 29 proteins were found only in the healthy subjects but absent in 
OSCC patients. Five candidate biomarkers M2BP, MRP14, CD59, profilin 1, and 
catalase were successfully validated using immunoassays on an independent set of 
OSCC patients and matched healthy subjects.
57 
                                   
Analysis of the pooled soluble fraction of whole saliva from four subjects with 
pre-malignant lesions and four with malignant lesions by mass spectrometry and 
prioritization of candidate biomarkers via bioinformatics with validation of selected 
proteins by western blotting revealed increased levels of myosin and actin in patients 
with malignant lesions.
58
  
 
 Identification of candidate protein and mRNA biomarkers of primary Sjogren 
syndrome in WS samples by Mass spectrometry and expression microarray profiling 
revealed sixteen WS proteins down-regulated and 25 WS proteins up-regulated in 
primary Sjogren Syndrome patients compared with matched healthy control subjects.
59  
Multidimensional liquid chromatography/tandem mass spectrometry (2D-LC-
MS/MS) with Label-free quantification has been used to identify protein biomarkers in 
whole saliva from type-2 diabetic individuals and compared with selected protein 
biomarkers were then validated in saliva from control, diabetic, and prediabetic 
subjects by Western immunoblotting and ELISA. This identified a total of 487 unique 
proteins. Approximately 33% of these proteins have not been previously reported in 
human saliva. Of these, 65 demonstrated a greater than 2-fold difference in levels 
between control and type-2 diabetes samples.
60
                
 
 
MICROARRAY
 
  Microarray-based assay technology provides investigators with the ability to 
measure the expression profile of thousands of genes in a single experiment. With the 
use of a QIAamp Viral RNA kit RNA was isolated from saliva supernatant and 
aliquots of RNA were treated with RNase-free DNase and then subjected to linear 
amplification in a RiboAmp™ RNA Amplification kit. Gene expression analysis of 
these samples using the Human Genome U133A Array. Two hundred seven probe 
sets, representing 185 genes, were detected among all 10 participants. 570 genes 
present in 8/10 (80%) arrays, and 417 genes in 9/10 (90%) arrays were found using the 
same criterion. Among these, 49 and 37 salivary mRNAs, respectively, were found to 
be present in saliva at protein levels as determined by proteomic approaches. The 
 genes present among all 10 arrays (100%) were referred to as “Normal Saliva Core 
Transcriptome (NSCT).
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POLYMERASE CHAIN RECTION (PCR) AND IMMUNOASSAYS      
The techniques like quantitative PCR and ELISA are used initially to validate 
the biomarkers identified as a result of proteomic and transcriptomic technologies. In a 
study using reverse transcriptase preamplification- quantitative PCR (RT-preamp-
qPCR) in 12 healthy controls a total of 314 miRNAs were measured. Selected 
miRNAs were validated in saliva of 50 oral squamous cell carcinoma patients and 50 
healthy matched control subjects. Significantly lower levels of miR-125a and miR-
200a were detected in the saliva of OSCC patients than in control samples.
62
.  
         Assessment of salivary profiles of patients with Erosive lichen planus by ELISA 
after being treated with prednisolone revealed a significantly higher level of IFN-γ, 
TNF-α, and sTNFR-2 was detected in patients before treatment than in controls. The 
salivary levels of IFN-γ, TNF-α and sTNFR-2 were found to be decreased significantly 
following treatment, when compared to their pre-treatment levels.
47
 
Detection of levels of proinflammatory cytokines Interleukin 1α (IL-1 α), 
Interleukin (IL-6), Interleukin (IL-8) and Granulocyte Macrophage-Colony 
Stimulating Factor (GM-CSF) was done by enzyme linked immunosorbent assay 
(ELISA). Higher concentrations of Serum IL-6 and IL-8 level were detected in patients 
with OSCC than the control group. And the levels of IL-1 alpha, IL-6, IL-8 and GM-
CSF in saliva showed significant increase in patients with OSCC when compared with 
control group. Serum and salivary IL-8 were proved to be useful in the diagnosis of 
OSCC patients and separating between OSCC patients and control group.
63
 
 Simple and inexpensive sampling method is a compelling reason to make 
saliva a reliable diagnostic tool. Moreover it causes minimal subject discomfort and is 
a source of definitive disease-associated protein and genetic markers. The advantage of 
easy collection, storage, shipping, and voluminous sampling, makes saliva a better 
diagnostic biofluid than serum or urine. It is also easier to handle saliva during 
diagnostic procedures than blood. Thus saliva can be used as an accurate, portable and 
easy-to-use diagnostic platform.  
 
LIMITATIONS OF USING SALIVA AS A DIAGNOATIC TOOL 
Although saliva has many advantages in case of ease of sample collection and 
handling it also carries some limitations. The level of certain markers in saliva is not 
the exact amount present in serum. A defined relationship is required between the 
concentration of the biomarker in serum and the concentration in saliva for a proper 
diagnosis.              
The detection of salivary biomarkers with diagnostic value depends on the 
normal functioning of the salivary glands. The degree of stimulation of salivary flow 
and the method of collection highly influences the composition of saliva. 
Concentration and availability of the biomarkers are affected by the changes in 
salivary flow rate and pH. Salivary flow rate varies between individuals and in the 
same individual under various conditions (diurnal variations, degree of hydration). 
Many serum markers and proteins can enter saliva through gingival crevicular 
fluid (GCF). This may affect the diagnostic quality of many salivary markers. 
Moreover certain systemic disorders, medications, and radiation may affect salivary 
gland function and consequently the quantity and composition of saliva. 
 In the technical aspect the most serious disadvantage of saliva is the instability 
if its constituents. This is mainly due to the proteolytic enzymes derived from the host 
and from oral micro-organisms. These enzymes can significantly affect the stability of 
certain diagnostic markers. Some molecules are also degraded during intracellular 
diffusion into saliva. Advent of many chemicals like protease inhibitors, ethanol etc 
and storage of the samples under very low temperature (
-
80
o
celsius) has helped the 
researchers to overcome this limitation to an extent.
42,64,65
   
 
RECENT ADVANCES AND USES 
The first step in the growth of saliva as a diagnostic tool is the discovery of 
informative biomarkers. Biomarker discovery in saliva is done by molecular 
techniques like genomics,proteomics, transcriptomics and metabolomics as mentioned 
before. With these techniques the genes, proteins, mRNAs and metabolites in saliva 
have been characterized by Based on these platforms different advanced technologies 
like  microfluidics and micro/nano electromechanical system (MEMS/NEMS) have 
been invented to serve as point of care devices. In this system multiple analytes in a 
drop of saliva could be simultaneously measured and analyzed through highly 
sensitive biosensors.
65  
The device invented in UCLA, California has been labelled the Oral Fluid 
NanoSensor Test (OFNASET). The OFNASET is a point-of-care, automated, and 
easy-to-use integrated system that will enable simultaneous and precise detection of 
multiple salivary proteins and nucleic acids. In addition, this system is portable and 
could be used not only in the doctor’s office, but also in any other healthcare station to 
perform an instant point-of-care diagnosis
43 
 INTERLEUKIN 1 B (IL1B) 
IL-1 was first described as a protein that induced fever and was called human 
leukocytic pyrogen and also it was known previously as lymphocyte activating factor 
(LAF). IL 1 is a 17-kilodalton (kD) glycoprotein which is made up of 2 major proteins, 
IL-1A and IL-1B.
66
 There are 11 members of the IL-1 family. IL-1A and IL-1B have 
minimal sequence homology but they have similar biological properties. They differ 
from each other fundamentally in their localization, maturation, and secretion. IL-1 is a 
pluripotent cytokine responsible for normal physiological roles including induction of 
vascular permeability, fever, secretion of additional cytokines in autoimmune diseases, 
production and release of prostaglandins, pituitary hormones, and collagenases and 
stimulation of the immune system to produce lymphocytes. An important balance 
exists between the beneficial and harmful effects of IL-1. IL-1 acts as an endogenous 
pyrogen and is a potent proinflammatory cytokine. It has potentiating effects on cell 
proliferation, differentiation, and function of many innate and specific 
immunocompetent cells. IL-1 initiates and potentiates immune and inflammatory 
responses and thereby mediates many inflammatory diseases. The IL-1 receptor 
antagonist (IL-1Ra) is synthesized and released in response to the same stimuli that 
lead to IL-1 production.
67
  
In human breast carcinoma IL-1 levels were significantly higher in invasive 
carcinoma than in ductal carcinoma in situ or in benign lesions, implying that elevated 
levels of IL-1 are directly correlated with a more advanced disease.
68
 Neoplastic cells 
directly produce IL-1 or can induce cells within the tumor microenvironment to do so. 
IL-1 shows various expression patterns: it is expressed in an autocrine or paracrine 
fashion. It stimulates the tumor cell by exhibiting autocrine behaviour by itself to 
 invade and proliferate and it can also exert paracrine effects on stromal cells in the 
tumor microenvironment. The exact mechanisms by which IL-1 promotes tumor 
growth remain unclear, though the protein is believed to act primarily indirectly 
(Figure 3). IL-1 induces expression of matrix metallo proteinases (MMP) and 
stimulates nearby cells to produce angiogenic proteins and growth factors such as 
VEGF, IL-8, IL-6, TNFα, and tumor growth factor beta (TGFβ) which helps in 
invasion and metastasis.(Annexure VIII) In the tumor microenvironment IL-1 has local 
effects on host infiltrating cells that result in production of proangiogenic and 
prometastatic mediators. It has been shown in some studies that IL-1 is necessary for 
tumor growth, metastasis, and angiogenesis.
18,19,69 
In a study where the amounts of IL-1 beta in the biopsied specimens of normal 
oral mucosa, oral submucous fibrosis (OSF), oral squamous cell carcinoma (OSCC), 
and verrucous hyperplasia (VerH) were quantified by ELISA,  a significant difference 
in IL-1 beta level was found between normal oral mucosa and OSCC . 
Immunohistochemistry staining technique using antibody against IL-1 beta showed 
positive staining in hyperplastic epithelium and neoplastic cells of OSCC. The amount 
of IL-1 beta did not change significantly as OSF progressed. The gradual increase in 
the levels of IL-1 beta from normal oral mucosa through verrucous hyperplasia  to oral 
squamous cell carcinoma  suggests that IL-1 beta plays an important role in oral 
carcinogenesis.
70
  
Distinct mRNA expression patterns can be identified in saliva from cancer 
patients, and the differentially expressed transcripts has been studied which can serve 
as biomarkers for cancer detection. In a study where Microarray analysis of 
unstimulated saliva collected from 32 patients with primary T1/T2 OSCC and 32 
 normal subjects with matched age, gender, and smoking history showed there are 
1,679 genes exhibited significantly different expression level in saliva between cancer 
patients and controls. Seven cancer-related mRNA biomarkers that exhibited at least a 
3.5-fold elevation in OSCC saliva were consistently validated by qPCR on saliva 
samples from OSCC patients and controls. These salivary RNA biomarkers are 
transcripts of IL8, IL1B, DUSP1, HA3, OAZ1, S100P, and SAT of which IL1B 
showed 5.48 fold increase in OSCC when compared to normal controlsThe 
combinations of these biomarkers yielded sensitivity (91%) and specificity (91%) in 
distinguishing OSCC from the controls. The utility of salivary transcriptome 
diagnostics is successfully demonstrated in this study for oral cancer detection.
71
   
To know if the above mentioned biomarkers are (IL8, IL1B, DUSP1, HA3, 
OAZ1, S100P, and SAT) discriminatory in cohorts of different ethnic background 
(Serbian population), mRNA transcripts of DUSP1, IL8, IL1B, OAZ1, SAT1, and 
S100P and three proteins IL1B, IL8, and M2BP were tested on 18 early and 17 late 
stage OSCC patients and 51 healthy controls with quantitative PCR and ELISA. Four 
transcriptome (IL8, IL1B, SAT1 and S100P) and all proteome biomarkers were 
significantly elevated in OSCC patients when compared to controls. The 
sensitivity/specificity for OSCC total was 0.89/0.78, for T1–T2 0.67/0.96, and for T3–
T4 0.82/0.84. Seven of the nine salivary biomarkers (three proteins and four mRNAs) 
showed highly significant performance in late stage cancer. IL1B showed 3.96 fold 
increase in OSCC when compared with normal controls. The previously discovered 
and validated salivary OSCC biomarkers were proved to be discriminatory and 
reproducible in a different ethnic cohort.
9
  
 In a study using Luminex Multianalyte Profiling (xMAP) technology for 
measurement of salivary proteins for IL1B and IL8 in 20 OSCC patiens and controls, 
both the markers were significantly elevated
72
And the measured levels of IL-8 in the 
saliva of OSCC subjects from this study were also comparable with those measured by 
ELISA from another group of researchers (Rhodus et al, 2005)
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INTERLEUKIN 8 (IL8) 
 Interleukin-8, also known by different other names: CXCL 8, monocyte-
derived neutrophil chemotactic factor (MDNCF) and neutrophil attractant/ activation 
protein (NAP- 1 ) is a 10 kD glycoprotein and was originally isolated from human 
peripheral blood monocytes.
57 
There are two cell-surface G protein–coupled receptors 
for IL 8 termed as CXCR1 and CXCR2 which mediate it’s the biological effects. 
Expression of IL-8 is primarily regulated by activator protein and/or nuclear factor-
kappa B (NF-κB) mediated transcriptional activity. Expression of IL-8 has been shown 
to be regulated by a number of different stimuli including inflammatory signals (e.g., 
tumor necrosis factor a, IL-1h), chemical and environmental stresses (e.g., exposure to 
chemotherapy agents and hypoxia), and steroid hormones (e.g., androgens, estrogens, 
and dexamethasone).
19
  
Increased expression of IL-8 and/or its receptors has been characterized in 
cancer cells, endothelial cells, infiltrating neutrophils, and tumour-associated 
macrophages. This suggests that IL-8 may function as a significant regulatory factor in 
the tumour microenvironment. The induction of IL-8 signalling activates multiple 
upstream signalling pathways (Annexure IX). These pathways regulate numerous 
transcription factor activities which result in gene expression. This also modulates the 
 cellular proteome at the level of translation and also effect the organization of the cell 
cytoskeleton through post translational regulation of regulatory proteins. IL-8 
signalling promotes angiogenic responses in endothelial cells, increases proliferation 
and survival of endothelial and cancer cells, and potentiates the migration of cancer 
cells, endothelial cells, and infiltrating neutrophils at the tumour site as a result of the 
diversity of effectors and downstream targets.  
Secretion of IL-8 from cancer cells enhances the proliferation and survival of 
cancer cells through autocrine signaling pathways. Tumor derived IL-8 can activate 
endothelial cells in the tumor vasculature to promote angiogenesis and induce a 
chemotactic infiltration of neutrophils into the tumor site. IL-8 also contributes to 
promote cell invasion and migration. The induction of tumor-associated macrophages 
to secrete additional growth factors by IL-8 will further increase the rate of cell 
proliferation and cancer cell invasion at the tumor site. The ability of IL-8 signalling to 
induce different cell types present within the tumor microenvironment suggests that 
targeting of CXC-chemokine may have implications on limiting disease progression 
and it also have potential to assist in sensitizing tumors to chemotherapeutic and 
biological agents.
68
 IL-8 is found as a useful serum marker for predicting the prognosis 
of pancreatic cancer. 
In a previously mentioned study where distinct mRNA expression patterns of 
IL8, IL1B, DUSP1, HA3, OAZ1, S100P and SAT were identified in saliva from 
cancer patients with microarray and consistently validated by qPCR on saliva samples 
from OSCC patients and controls,  IL8 performed the best among others giving 24.3 
fold increase, 88% sensitivity and 81% specificity ensuring the utility of IL8 in oral 
cancer detection.
71
      
 In another study which was done to evaluate these markers in a different cohort  
with quantitative PCR and ELISA, among the other transcriptome and proteome 
biomarkers  IL8 showed 3.9 fold increase and proved to be discriminatory and 
reproducible in a different ethnic cohort.
9
  
IL 6 and IL 8 has been investigated in mRNA and protein levels in saliva and 
serum of patients with OSCC and controls using quantitative polymerase chain 
reaction PCR and ELISA respectively. IL-8 at both the mRNA and protein levels was 
detected in higher concentrations in the saliva of patients with OSCC compared with 
controls. Significant difference in the amount of IL-8 mRNA expression has been 
identified. The level of IL-8 in the saliva of OSCC patients was 720 pg/mL which was 
significantly higher than that in the saliva of the control group which was 250 pg/mL. 
A comparison of the total protein concentrations in saliva between the 2 groups was 
done in order to ensure that the elevated levels of IL-8 protein in saliva were not due to 
an elevation of total protein levels in the saliva of patients and no significant 
differences were found.  There was no significant difference in the IL-6 levels between 
the 2 groups in the salivary concentration at either the mRNA or the protein level. In 
contrast the serum analysis showed that levels of IL 6 was significantly elevated in 
OSCC patients with insignificant IL 8 levels.
11
  
The levels of proinflammatory cytokines IL-1, IL-6, IL-8 and Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF) have been investigated by ELISA. 
IL-6 and IL-8 levels in serum were detected at higher concentrations in patients with 
OSCC than the control group. No significant differences in serum IL-1 alpha and GM-
CSF of patients with OSCC was identified when compared with control group. The 
levels of IL-6, IL-8, IL-1 alpha and GM-CSF showed significant increase in saliva of 
 patients with OSCC when compared with control group. Serum IL-6 was more 
significant in OSCC patients than salivary IL-6. Both serum and salivary IL-8 were 
significant in OSCC patients and it is proved to be useful in separating OSCC patients 
and control group.
62
  
In another study where the concentration of tumor necrosis factor α, interleukin 
1α, 6, and 8 in the saliva of oral squamous cell carcinoma patients with control group 
were compared using ELISA, the concentration of salivary interleukin 6 in oral 
squamous cell carcinoma patients was higher than control group and it was statistically 
significant. The concentration of salivary tumor necrosis factor α, interleukin 1α and 8 
in case group was higher than control group but it was not statistically significant.
74 
  
Higher levels of IL 1B, IL 8, IL6 and osteopontin have been identified in 
OSCC when compared to controls using ELISA. But the difference was shown to be 
significant only in IL 6 concentrations.
75
 Estimation of serum and salivary samples of 
patients with OSCC and OPMD for a panel of tumor markers Cyfra 121-1, IL 6, IL 8, 
and TNF alpha by ELISA revealed significant elevation of levels of Cyfra 121-1, IL 6, 
IL 8, and TNF alpha in IL 6, IL 8 in saliva. The levels of these markers were 
significantly higher in serum also except for Cyfra 121-1.
46
  
Another study on proangiogenic and proinflammatory cytokines in 2005 which 
was done on TNF-alpha, IL-1, IL-6, and IL-8 showed elevated levels of IL 8 in the 
saliva of patients with OSSC and OPML (oral potentially malignant lesions) as 
compared to controls.
7 3
 Result of a study in India done on 25 OSCC patient by ELISA 
suggested that salivary IL-8 can be utilised as a potential biomarker for OSCC but it 
was found to be non-conclusive for oral pre-malignancy. 
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Results 
 
 The study group comprised of 72 subjects including 18 subjects with OSCC, 
30 with OPMD and 24 controls grouped under Group I, Group II and Group III 
respectively. Group II was subdivided into subjects with oral submucous fibrosis 
(Group II A) and subjects with leukoplakia (Group II B). Group III comprised of 
controls including 12 patients with periodontitis and 12 healthy controls. (Graph 1, 
Table 1) As the sample size was small OSCC and leukoplakia was not further stratified 
based on differentiation and level of dysplasia respectively.  
 
Gender and age distribution among study groups 
Among the overall study population (n=72) 80.6% were males (n=58) and 
19.4% were females (n=14). In Group I (n=18) 88.9% (n=16) were males and 11.1% 
(n=2) were females. In Group II A all the subjects (100%) were males (n=16). In 
Group II B (n=14) 92.9% (n=13) were males and this group included only one female 
(7.1%). In Group III (n=24) 54.2% (n=13) were males and 45.8% (n=11) were 
females. (Graph 2, Table 2) 
The age of the subjects ranged from 25 to 83 years with the mean of 42.1 ± 
12.5. The age distribution among Groups I, II A, II B and III are 51 ± 14.9, 39.3 ± 10, 
42.4 ± 12.6 and 37.1 ± 8.5 respectively. (Graph 3, Table 3) 
 
Prevalence of habits among study groups 
The number of subjects who had the habit of smoking were 11 (61.1%), 6 
(37.5%), 6 (42.9%), and 3(12.5%) in Groups I, II A, II B, and III respectively. Group I 
included 16 (88.9) subjects while all subjects in Group II A (100%) and 10 (71.4%) 
subjects in Group II B had chewing habit. The number of subjects who had drinking 
 habit was  8 (44.4%), 13 (81.3%) and 10 (71.4%) in Group I, II A and II B 
respectively.(Graph 4, Table 4) No subjects in Group III had chewing or drinking 
habit.  
 
Levels of Interleukins in study groups 
IL 8 
The mean concentration of IL 8 in the study population was found to be 
1079.31 ± 424.57 in Group I, 629.95 ± 590.01 in Group II A, 711.5 ± 366.25 in Group 
II B and 671.53 ± 485.17 in Group III.( Graph 5, Table 5) The differences in the 
groups were statistically significant (P=0.023). Multiple comparisons between the 
groups was done using Tukey HSD test.  
The concentration of IL 8 was found to be elevated in Group I when compared 
to other groups. Comparison of Group I with group II A (P=0.038) and Group III 
(P=0.038) was statistically significant while the comparison with Group II B showed 
no statistical significance (P=0.143). Comparison of Group II A with Group II B 
(P=0.966) and Group III (P=0.993) also showed no statistical significance. Group II B 
and Group III also showed no statistical significance (P=0.995) when compared. 
 
IL 1B 
The mean concentration of IL 1 B was found to be 1086.14 ± 758.29, 514.25 ± 
505.7, 1073.84 ± 799.93 and 535.36 ± 477.88 in Groups I, IIA, IIB and III 
respectively. (Graph 6, Table 6) The differences in the groups were statistically 
significant (P=0.006). In multiple comparisons, comparison between Group I and 
Group III only was statistically significant (P=0.033). Comparisons between other 
 groups Group I with Group II A (P=0.05) and Group II B (P=1.0), Group II A with 
Group II B (0.83) and Group III (1.0) and Group II B with Group III (P=0.64) were 
statistically not significant.    
 
Comparison with group IIIA and B separately 
When IL 8 and IL1B concentrations were compared with the control group 
with periodontitis (group IIIA) and without periodontitis (group IIIB), we found group 
IIIA and B showed no statistical significance when compared separately with groups I, 
IIA and IIB.(Graphs 7 and 8, tables 7 and 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables and Graphs 
 
 
 Graph 1 
Distribution of number of samples in different groups 
 
 
 
Table 1 
Distribution of number of samples in different groups 
 
 
18 
16 
14 
24 
Group I Group II A Group II B Group III  
Groups Type of sample Sample size 
Group I Oral squamous cell carcinoma 18 
Group II A Oral submucous fibrosis 16 
Group II B Leukoplakia 14 
Group III(A and B) Controls (Normals) 24 
 Graph 2 
Distribution of gender in study groups 
 
 
Table 2 
Distribution of gender in study groups 
Study Groups Male Female 
 n Percentage n Percentage 
Group I(n=18) n=16, 88.9% n=2 17.9% 
Group II A(n=16) n=16 100% n=0 0% 
Group II B(n=14) n=13 92.9% n=1 7.1% 
Group III(n=24) n=13 54.2% n=11 45.8% 
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 Graph 3 
Distribution of age in study groups 
 
 
Table 3 
Distribution of age in study groups 
Study Groups Mean age Standard deviation 
Group I(n=18) 51 14.7 
Group II A(n=16) 39.3 9 
Group II B(n=14) 42.4 12.6 
Group III(n=24) 37.1 8.4 
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 Graph 4 
Prevalence of habits in the study groups 
 
 
Table 4 
Prevalence of habits in the study groups 
Study Groups Smoking Chewing Alcohol 
 n Percentage n Percentage n Percentage 
Group I(n=18) 11 61.1% 16 88.9% 8 44.4% 
Group II (n=16) 6 37.5% 16 100% 13 81.3% 
Group II B(n=14) 6 42.9% 10 71.5% 10 71.4% 
Group III(n=24) 3 12.5% 0 0% 0 0% 
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 Graph 5 
IL 8 concentrations in study groups 
 
 
Table 5 
IL 8 concentrations in study groups 
Study Groups Mean 
Standard 
deviation 
P value 
Group I(n=18) 1079.31 424.57 
0.023* 
Group II A(n=16) 629.95 590.01 
Group II B(n=14) 711.5 366.25 
Group III(n=24) 671.52 485.17 
 
*Statistically significant at 5% level, P <0.05  
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Graph 6 
IL 1B concentrations in study groups 
 
 
Table 6 
IL 1B concentrations in study groups 
Study Groups Mean 
Standard 
deviation 
P value 
Group I(n=18) 1086.14 758.29 
0.006* 
Group II A(n=16) 514.25 505.79 
Group II B(n=14) 1073.84 799.93 
Group III(n=24) 535.36 477.88 
 
*Statistically significant at 5% level, P <0.05  
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 Graph 7 
Comparison of mean differences in IL 8 concentration between group I, IIA and IIB 
with group IIIA and IIIB 
 
 
Table 7 
Comparison of mean differences in IL 8 concentration between group I, IIA and IIB 
with group IIIA and IIIB 
Groups 
Mean difference 
with Group 
IIIA 
P value 
Mean difference 
with Group IIIB 
P value 
Group I(n=18) 439.58 0.1 375.99 0.23 
Group IIA(n=16) 9.78 1.0 -73.36 0.99 
Group IIB(n=14) 71.76 0.99 8.18 1.0 
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 Graph 8 
Comparison of mean differences in IL 1B concentration between group I, IIA and IIB 
with group IIIA and IIIB 
 
 
Table 8 
Comparison of mean differences in IL 1B concentration between group I, IIA and IIB 
with group IIIA and IIIB 
Groups 
Mean difference 
with Group 
IIIA 
P value 
Mean difference 
with Group IIIB 
P value 
Group I(n=18) 636.07 0.06 465.5 0.29 
Group IIA(n=16) 64.18 0.99 -106.4 0.99 
Group IIB(n=14) 623.77 0.1 453.19 0.37 
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Figures 
 
  
ARMAMENTARIUM 
 
Figure 1: Armamentarium Used For Specimen Handling and Elisa Procedure 
 
 
 
Figure 2: Cooling Centrifuge 
  
 
Figure 3: Micro-Centrifuge Tube 
 
 
 
 
Figure 4: IL 8 ELISA kit with reagents 
  
 
 
Figure 5: IL IB ELISA kit with reagents 
 
 
 
 
Figure 6: ELISA plate reader and washer 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
 Oral cancer is a serious debilitating disease which is a major health problem in 
our country
3,6
. As OSCC is associated with habits and occur mostly as a result of 
progression from precancerous states, early detection or prevention of OSCC is not too 
hard to achieve if there is an easier and non-invasive technique than biopsy for 
screening of people at risk.   The tumor microenvironment consists of different types 
of cells including tumor, immune, stromal, and inflammatory cells all of which 
produce cytokines, growth factors, and adhesion molecules. All these factors 
intimately interact with one another and play an important role in inflammatory and 
pro-angiogenic processes and thereby tumor progression and metastases.  
 Previous studies have shown that cytokines like IL8 and IL1B are elevated 
significantly in saliva of OSCC patients.
9,10,11,12
  These biomarkers can act as major 
targets for early detection of cancer. Most of these markers have been identified either 
in cancer cell lines or in biopsy specimens from cancers. The identification of 
molecular markers in bodily fluids that would predict the development of cancer in its 
earliest stage or in precancerous stage would constitute a non-invasive and convenient 
method. In case of oral cancer, as the neoplastic cells are immersed in the salivary 
milieu these molecular markers can be detected in saliva conveniently and 
efficiently.
77
 
The aim of our study was to find out if the levels of IL 8 and IL1B are altered 
in OSCC and OPMD when compared to normal subjects in a South Indian population. 
Though many studies have been done in Western countries 
9,10,11,72,73 
very few are done 
in India
74,45
. Our study population included three groups, group I- OSCC (n=18), 
group II – OPMD(n=30), group III – normal controls(n=24). Group II was subdivided 
into group II A – OSF (n= 16) and group II B – leukoplakia (n=14).  
 Enzyme-linked immunosorbent assay (ELISA) a powerful method for 
detecting and quantifying a specific protein in a complex mixture used in both 
experimental and diagnostic techniques. It is a highly sensitive technique that can 
detect proteins at the picomolar to nanomolar range. This technique was used in our 
study due to high sensitivity to detect proteins especially low abundant proteins like 
IL8 and IL1B, affordability of the cost factor and less laboratory demands. We found 
significant difference in expression of IL 8 and IL 1B in OSCC when compared to 
controls. 
 
IL8 
In our study the concentration of IL 8 was found to be elevated in OSCC when 
compared to the controls. This is in accordance with the studies which already have 
proven that IL 8 could be used as a biomarker to detect the presence of OSCC.
 9, 
10,11,73,74 
Though there was a difference between OPMD and controls, it was not 
statistically significant. We noted an increase in concentration of IL 8 in leukoplakia 
when compared to OSF which was also not statistically significant. We suggest that 
comparing more number of samples of leukoplakia with different stages of dysplasia 
are necessary to understand its significance.  
There was no significant difference between the OPMD and controls. This 
result is consistent with the result of a study by Punyani SR et al in 2012
75
. Our study 
demonstrates the reliability of IL8 as a biomarker for differentiating OSCC from 
normal. But our study also shows that IL8 cannot be used reliably to differentiate 
OPMD from normal.                                       
 An issue we encountered in IL 8 assay was higher values for standards in IL 8 
than given in the data sheet from the provider (Diaclone
TM
, France). This can be 
attributed to the factors like improper dilution of standards, improper handling during 
serial dilution, air bubbles in the pipette, touching the base of the wells with the 
pipette, time factor, and improper calibration of the ELISA reader. As we made sure 
that we avoided all these factors by proper handling and following the protocol this 
difference could be attributed to the environmental variation. Moreover the reading 
was duplicated with similar results and all the concentrations showed a higher 
absorbance value consistently in repetition. This led us to continue the assay and 
accept the results. 
 
IL 1B 
In the case of IL 1B also the concentrations were found to be significantly 
elevated in OSCC when compared to controls. This is consistent with the results of 
studies done by Katakura et al in 2007
76
 and Brinkman. O et al in 2011
9
.   
In our study on IL1B we encountered a problem of getting higher absorbance 
than the absorbance of the highest concentration in the standard curve for many 
samples. This is attributable to many factors like insufficient washing or blocking, 
sample components or antibodies cross-reacting with the blocking buffer or the use of 
too much enzyme conjugate, contamination etc. As we have repeated the readings after 
having ensured that any of these factors did not affect our assay, this could be due to 
the presence of higher concentration of IL 1B in our study samples beyond the range 
of that detectable by the technique. IL 1B is an innate immune cytokine which can be 
secreted by many cells in the oral mucosa. In a study by Kumar PS et al smokers 
 demonstrated significantly greater levels of IL 1 B.
78
 It has also been shown that even 
the commensal oral microflora can induce the secretion of IL1B through Toll-like 
receptors (TLR) in response to pathogen-associated molecular patterns (PAMPs) or 
IL-1B itself.
79
 It has also been proved that certain bacterial species/ phylotypes  may 
play a role in triggering chronic inflammation in oral cavity and possibly be associated 
at different stages of cancer in a study by Pushalkar et al.
 80 
         The high absorbance of the samples can also be attributed to the fact that the 
ELISA kit we used had a low detection range (6 - 500 pg/ml). Previous studies have 
demonstrated high levels of IL1B which is comparable with our result. Teles et al has 
demonstrated  753 ± 1022 pg/ml of IL1B in saliva of periodontitis subjects in 2009.
81
 
Moreover  IL-1B average levels in a study using single-plex assay  by Arellano-Garcia  
in 2008 were 945.2 ± 1134.8 pg ml−1 (OSCC(n = 20) and 314.2 ± 444.8 pg ml−1 
(control, n = 20) which is consistent with our study.
72 
          The samples which showed higher levels must ideally have been run in 
repetitions in different dilutions to get a value within the limit. We suggest that further 
studies should be done in different dilutions and also using a kit with a wider assay 
range to substantiate the higher values we got in our study. 
 In our study we also found that the level of IL 1B in OSCC and leukoplakia 
(Dysplasia) were similar in saliva. This shows that levels of IL 1B is increased with 
the presence of dysplastic lesions in the oral cavity when compared to OSF and 
normal. Further studies needs to be done in a larger sample size with OSCC and 
lekoplakia stratified based on differentiation and level of dysplasia respectively. 
 
 
 Comparison with group IIIA and B separately 
Our study group III consisted of 12 patients with periodontitis (group IIIA) and 
12 patients without periodontitis (group IIIB). When IL 8 and IL1B were compared 
with these subgroups, we found group IIIA and B showed no statistical significance 
when compared separately with groups I, IIA and IIB. The result we got is not 
conclusive as our sample size was not sufficient and we suggest validating these 
results by doing the study with a larger sample size.  
Cytokines are intercellular signalling proteins which play a role in regulating 
growth, cellular proliferation, angiogenesis and tissue repair. They also function in 
immune responses to infection, injury and inflammation. Some conditions such as 
rheumatoid arthritis, periodontal disease, osteoporosis, Sjögren’s syndrome, chronic 
parotitis, severe exercise and diabetes can give rise to increased levels of inflammatory 
proteins. Our control group included patients with periodontal disease (n = 12) and 
found that while they have slightly elevated IL-8 and IL 1B in saliva, patients with oral 
cancer have significantly higher saliva levels. This shows that although immunological 
and inflammatory diseases may increase cytokines levels, the levels are not as high as 
those found in OSCC patients. But we suggest that local as well as systemic 
immunological and inflammatory disease control group may be included for further 
validation of IL-8 and IL-1B as truly discriminatory markers for OSCC. 
                                            
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary and Conclusion 
 
  The study group included 18 OSCC (group I), 30 OPMD (16 OSF - group IIA), 
14 leukoplakia (group IIB) and 24 controls (group III, 12 with periodontitis 
(group IIIA and 12 without periodontitis (group IIIB)). 
 This study was done to detect and compare the levels of IL8 and IL1B in saliva 
of patients with OSCC, OPMD and control group 
 The technique, solid phase sandwich ELISA was used to identify and quantify 
the levels of IL8 and IL1B in study groups. 
 Mean concentrations of IL8 and IL 1B were assessed in all groups . 
 We found that the mean concentrations of both IL 8 and IL 1B were increased in 
OSCC and OPMD when compared to the control group. 
 In multiple comparisons, the concentration of  IL 8 was significantly increased  
in OSCC when compared with OSF (P<0.05) and control group (P<0.05).  
 The concentration of  IL 8 in OSCC was increased when compared with 
leukoplakia (P=0.14). 
 In multiple comparisons, the concentration of IL1B was increased in OSCC 
when compared to controls (P<0.05). 
 The concentration of IL1B in leukoplakia was similar to OSCC (P=1.0). 
 The concentration of IL1B was increased in OSF (P=0.83) as well as leukoplakia 
(P=0.64) when compared to controls.  
 When the multiple comparisons were done with groups IIIA and IIIB separately 
none of the comparisons showed statistical significance. 
 
 
 Salivary diagnostics is an emerging field which has high potential to 
revolutionize the field of laboratory diagnosis as it is non-invasive and allows easy 
specimen handling
80
. Our study shows that IL8 and IL1B are significantly elevated in 
saliva of patients with OSCC when compared to normal controls. This supports the 
invention of point of care devices for large scale screening for OSCC. More works like 
this need to be done using a larger sample size, before turning saliva diagnostics into a 
clinical and commercial reality. Studies like this contribute to the invention and 
commercialization of lab on chip assays using microfluidics
81
 and microbeads which 
would lead to early detection of serious fatal diseases like oral cancer, assessment of 
prognosis and treatment outcomes. 
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Annexures 
 
 
 
 ANNEXURE I 
DATA SHEET FOR IL 8 ELISA KIT 
Intended use 
The Diaclone IL-8 kit is a solid phase sandwich ELISA for the in-vitro 
qualitative and quantitative determination of IL-8 in supernatants, buffered solutions, 
serum and plasma or other biological samples. This assay will recognise both natural 
and recombinant human IL-8. 
 
Biotinylated anti-IL-8  
It is recommended this reagent is prepared immediately before use. Dilute the 
biotinylated anti-IL-8 with the biotinylated antibody diluent in an appropriate clean 
glass vial using volumes appropriate to the number of required wells  
 
 
 
 Data Analysis 
Calculate the average absorbance values for each set of duplicate standards, controls 
and samples. 
Generate a linear standard curve by plotting the average absorbance of each standard 
on the vertical axis versus the corresponding IL-8 standard concentration on the 
horizontal axis. 
The amount of IL-8 in each sample is determined by extrapolating OD values against 
IL-8 standard 
concentrations using the standard curve. 
Sensitivity - The sensitivity, minimum detectable dose of IL-8 using this Diaclone IL-
8 ELISA kit was found to be 29pg/ml.. 
Specificity - The assay recognizes both natural and recombinant human IL-8. To 
define the specificity of this ELISA several proteins were tested for cross reactivity. 
There was no cross reactivity observed for any protein tested (IL-1a, IL-1b, IL-10 IL-
12, IFNg, IL-2, IL-6, TNFa, IL-4 and IL-13). 
 
 
 
 
 
 
 
 
 
 ANNEXURE II 
DATA SHEET FOR IL1B ELISA KIT 
Intended use 
The Diaclone IL-1B ELISA kit is a solid phase sandwich ELISA for the in-
vitro qualitative and quantitative determination of IL-1B in supernatants, buffered 
solutions or serum, plasma and other biological samples. This assay will recognise 
both natural and recombinant human IL-1B. 
 
Biotinylated anti IL-1B 
It is recommended this reagent is prepared immediately before use. Dilute the 
biotinylated anti IL-1B with the biotinylated antibody diluent in an appropriate clean 
glass vial using volumes appropriate to the number of required wells 
 
 
 
 Data Analysis 
Calculate the average absorbance values for each set of duplicate standards, 
controls and samples. Generate a linear standard curve by plotting the average 
absorbance of each standard on the vertical axis versus the corresponding IL-1B 
standard concentration on the horizontal axis. The amount of IL-1B in each sample is 
determined by extrapolating OD values against IL-1B standard concentrations using 
the standard curve. 
 
Sensitivity 
The sensitivity or minimum detectable dose of IL-1B using this Diaclone IL-
1B ELISA kit was found to be 6.5 pg/ml. 
 
Specificity 
The assay recognizes both natural and recombinant human IL-1B. To define 
the specificity of this ELISA several proteins were tested for cross reactivity. There 
was no cross reactivity observed for any protein tested (IL-1a, IL-2, IL-10, IL-12, IL-
17A, IL-23, IFNg, Gp130, IL-33, TNFa). 
 
 
 
 
 
 
 
 ANNEXURE -III 
 
From,          Date: 26.09.2011 
Institutional Review Board,  
Ragas Dental College and Hospital,  
Uthandi, Chennai 
 
 
 The dissertation topic titled ‘Study of interleukin 8 and interleukin 1b in 
saliva of patients with oral squamous cell carcinoma and oral potentially 
malignant disorders’ submitted by Dr. Aiswarya Lekshmy.S.U  has been approved 
by the Institutional Review Board of Ragas Dental College and Hospital on 26th 
September 2011. 
 
 
 
Dr.K.Ranganathan     Dr.S.Ramachandran 
Secretary,      Chairman, 
Ragas, IRB       Ragas, IRB 
 
 
 
 ANNEXURE: IV 
Consent Form 
I, ………………………………………………….. s/o, w/o, 
d/o……………………………………………, aged about………. years, 
Hindu/Christian/Muslim/ ………………………………….residing at                      
…………………………………………………………………………………………
…, do hereby solemnly and state as follows. I am the deponent herein; as such I am 
aware of the facts stated here under.  
I was informed and explained about the pros and cons of the study/test in the 
…………… language known to me. 
I was also informed and explained that the results of the individual test will not be 
revealed to the public. I give my consent after knowing full consequences of the 
dissertation/thesis/study and I undertake to cooperate with the doctor for the study. 
I also authorize the doctor to proceed with further treatment or any 
other/suitable/alternative method for the study. 
I have given voluntary consent to undergo the treatment with out any individual 
pressure or duress.    
I am also aware that I am free to withdraw the consent given at any time during the 
study in writing. 
Signature of the Patient/Attendant 
The patient was explained the procedure by me and he has understood the same and 
signed in                  
 (English/Tamil/Hindi/Telugu/…………………….) before  me. 
Signature of the Doctor        
 ANNEXURE: V 
Standard curve with concentrations of IL8 in x-axis and corresponding   optical 
density (OD) in y-axis 
 
 
Standard curve with concentrations of IL1B in x-axis and corresponding   optical 
density (OD) in y-axis 
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ANNEXURE: VI 
 
 
Composition and functions of saliva 
Components of saliva and associated functions are depicted in the figure. 
(AV Nieuw Amerongen, ECI Veerman. Saliva - the defender of the oral cavity. Oral 
Diseases.2002: 8; 12-22) 
 
 
 
 
  
ANNEXURE: VII 
 
Contributions of different salivary glands to whole saliva volume 
 
Gland Saliva type Contribution to volume 
Parotid Serous 25% 
Submandibular Mixed 60% 
Sublingual Mixed 7%-8%, 
Minor glands Mucous 7%-8% 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 ANNEXURE: VIII 
 
 
 
IL-1 indirectly alters tumor growth and metastatic potential
 
Lewis AM, Varghese S, Xu H, Alexander RH.  Interleukin-1 and cancer progression: 
the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in 
cancer treatment Journal of Translational Medicine 2006, 4:48 
 
  
 
 
 
 
 ANNEXURE: IX 
 
 
IL 8 Pathway  
Range of signaling pathways that are activated after stimulation of IL8 receptors 
(Waugh DJJ and Wilson C. The Interleukin-8 Pathway in Cancer  
Clin Cancer Res 2008;14: 6735-6741). 
 
 
 
 
 
 
 
 
 ANNEXURE:XB 
 
MASTER  CHART 1 STUDY GROUPS (GROUPI, IIA AND IIB) 
 
 
 
 
 
 
 
 
 
 
 
 ANNEXURE:XB 
MASTER CHART II CONTROL  GROUP (GROUP IIIA AND B) 
Case 
no 
Sample 
no Age  Gender Periodontitis MH Habits Il 8 Il 1b 
1 CP001 40 F yes no no 0 353.4 
2 CP002 38 F yes no no 344 24.99 
3 CP003 55 F yes hypr no 1332 193.7 
4 CP004 50 F yes no no 0 581.5 
5 CP005 52 M yes diab Smoking 54.53 0 
6 CP006 35 M yes no no 1297 19.02 
7 CP007 42 M yes no no 1420 196.4 
8 CP008  35 M yes no no 741.9 972.11 
9 CP009 35 M yes no no 968.1 1529 
10 CP010 43 F yes no no 339.5 584.6 
11 CP011 31 F yes no no 1105 478.3 
12 CP012 46 M yes no no NO 74.83 
13 CN001 29 M no no no 957.4 137.2 
14 CN002 28 F no no no 157.2 164.4 
15 CN003 29 F no no no 1215.1 1002 
16 CN004 40 M no no no 1332 -4.88 
17 CN005 30 M no no no 0 25.23 
18 CN006 25 M no no no 472 1421 
19 CN007 27 F no no no 787 745.9 
20 CN008 28 F no no no 871.1 1232 
21 CN009 35 M no no no 425.3 163.5 
22 CN010 31 F no no no 460.4 662.7 
23 CN011 45 M no no no 688.3 718.7 
24 CN012 42 M no no no 1074 1180 
 
MH - Medical History 
hyp - hypertension 
diab - diabeties 
 
